在兽医中制药化合物:停用伊特拉科纳
Gema J Cabañero-Resta1,2, Bárbara Sánchez-Dengra3, Alejandro Ruiz-Picazo3
1Departamento de Farmacia y Tecnología Farmacéutica y Parasitología, Universitat de València, Vicente Andrés Estelles s/n, Burjassot, 46100 Valencia, Spain.
Pharmaceutics
|May 25, 2024
概括
将伊特拉科纳与基甲基纤维素和β-cyclopodextrin结合起来,可以产生新的口服配方. 这些配方改善药物溶解和肠道吸收,用于治疗动物皮肤植物病.
科学领域:
- 兽医药房 兽医药房 兽医药房
- 制药技术 制药技术 制药技术
- 皮肤病学 皮肤病学
背景情况:
- 伊特拉科纳对于治疗动物皮肤植物病至关重要,但现有的配方限制了其使用.
- 目前西班牙的伊特拉科纳悬浮剂对于大型动物或群体治疗是不够的.
- 伊特拉科纳的溶解性较差和潜在的十二指肠沉 (生物制药分类系统II类) 阻碍了口服生物可用性.
研究的目的:
- 开发和表征用于兽医的替代口服伊特拉科纳配方.
- 通过制药复合来克服现有的伊特拉可纳药品的局限性.
- 为了提高伊特拉科纳的溶解,稳定性和肠道透性,以提高疗效.
主要方法:
- 准备和评估各种伊特拉科纳口服化合物.
- 溶解速度,肠道透性和稳定性的比较分析.
- 使用诸如基烯甲基纤维素和β-环氧素之类的辅助剂.
主要成果:
- 一种结合基甲基纤维素和β-cyclopodextrin的新型配方表现出卓越的性能.
- 这种配方实现了与参考产品相比的溶解.
- 它有效地延迟了胃排空后的伊特拉可纳沉,并增加了两倍以上的肠道透性.
结论:
- 复合伊特拉可纳配方为商业产品提供了可行的替代品.
- 开发的配方增强了伊特拉科纳在治疗皮肤植物病中的药理动力学特征.
- 基烯基甲基纤维素和β-cyclopodextrin是有效的辅助剂,可以改善伊特拉科纳的口服.
相关概念视频
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
129
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
129
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
198
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
198
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
299
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
299